MihaelaCristeaMD

Oncology • Duarte, CA

Associate Professor

Join to view full profile

Dr. Cristea is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cristea's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-359-8111

Fax+1 626-218-5310

Education & Training

University of Florida College of Medicine JacksonvilleFellowship, Hematology and Medical Oncology, 1998 - 2000
Rutgers Health/Monmouth Medical CenterResidency, Internal Medicine, 1995 - 1998
University of Medicine and Pharmacy ‘Gr T Popa” Iasi Class of 1992

Certifications & Licensure

NC State Medical License 2000 - Present
CA State Medical License 2004 - 2026
FL State Medical License 1999 - 2006
MI State Medical License 1997 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity Start of enrollment: 2009 Jan 01
Completed
Phase 1
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer Start of enrollment: 2012 Dec 03
Completed
Phase 2
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Start of enrollment: 2013 Apr 29
Active, not recruiting
Phase 2
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Start of enrollment: 2017 Mar 22
Completed
Phase 1
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2018 Feb 01
Active, not recruiting
Phase 2
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Start of enrollment: 2019 Jul 03
Suspended
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receivi...
Joyce F Liu, Niya Xiong, Robert M Wenham, Andrea Wahner-Hendrickson, Deborah K Armstrong
Gynecologic Oncology. 2024-08-01
5 citations
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
Antons Martincuks, Chunyan Zhang, Theresa Austria, Yi-Jia Li, Rui Huang
Journal for Immunotherapy of Cancer. 2024-04-05
5 citations
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer...
Mihaela C Cristea, Daphne Stewart, Timothy Synold, Nora Ruel, Joanne Mortimer
Gynecologic Oncology. 2024-03-01

Lectures

A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC),...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

City of Hope Presents New Cancer Research at American Society of Clinical Oncology MeetingMay 31st, 2016